Are atopic dermatitis treatments also effective for vitiligo?

Yes. In 2023, the International Vitiligo Task Force, through expert consensus, recommended Protopic and ELIDEL as first-line treatment options for vitiligo in specific areas.

The recommendation states that it should be applied twice daily, with treatment efficacy evaluated after the initial 6 months, and if necessary, it can be used long-term for 12 months or more.

Another advantage is that, compared to conventional topical steroids, there is less concern about side effects such as skin atrophy.

Similar opinions were presented in a Delphi study conducted among domestic vitiligo experts.

In other words, Protopic and ELIDEL are not merely used empirically; they are recognized as treatment options for vitiligo by expert consensus both domestically and internationally.

Protopic and ELIDEL are not officially approved by the Korea Ministry of Food and Drug Safety as treatments for vitiligo.

Nevertheless, health insurance coverage for vitiligo treatment was applied because domestic and international research results and clinical experience have accumulated.

Medical experts, including the Korean Vitiligo and Pigment Society, requested expanded health insurance coverage based on these research data and clinical experience.

At that time, there was a lack of officially approved drugs for vitiligo treatment, and patients had limited options for more effective treatment.

Considering this situation and the actual treatment needs, even when used outside the approved indications, health insurance coverage can be applied if certain conditions are met.

The Ministry of Health and Welfare established health insurance coverage criteria for Protopic and ELIDEL in vitiligo treatment through Notice No. 2019-57 on March 27, 2019, and it has been applied since April 1, 2019.

The main criteria for coverage are as follows.

In other words, health insurance does not cover vitiligo on all parts of the body; under current criteria, vitiligo on the face and neck is the covered indication.

For Protopic, in children, coverage is recognized only for the 0.03% low-concentration formulation.

The long-term safety of Protopic and ELIDEL has been continuously studied.

Initially, concerns were raised about the risk of malignant tumors such as lymphoma and skin cancer, but subsequent large-scale follow-up studies and meta-analyses have reported that the risk of malignant tumors does not increase when used as directed.

Additionally, the burden of side effects such as skin atrophy, telangiectasia, and striae that can occur with long-term use of steroid ointments is relatively lower, offering the advantage of being usable on thin and sensitive facial skin.

However, there are a few precautions.

- Do not use on areas with active skin infection

- Avoid excessive sun exposure after applying the medication

- Use sunscreen if necessary

- Use with caution in infants under 2 years of age

The health insurance coverage of Protopic and ELIDEL is meaningful for vitiligo patients in that it expands treatment options and reduces the cost burden of long-term treatment.

In particular, as treatment options for vitiligo on visible areas such as the face and neck are included in the health insurance system, more consistent treatment has become possible.

Going forward, it will be necessary to keep an eye on the expansion of coverage criteria to areas other than the face and neck and whether new vitiligo treatments will be covered by health insurance.